GlassScriptPhysician profile
George R Dibu
NPI 1598992059
$8,104.47
in general payments reported to CMS, 2019-2025
38 companies · $2,237 in 2025
The $2,237 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,141 · 2020: $147 · 2021: $580 · 2022: $1,377 · 2023: $1,281 · 2024: $342 · 2025: $2,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,857 · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,857.43 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,391.59 | 2019-2025 | Triclip, Mitraclip, Navitor |
| Abiomed | $1,358.64 | 2019-2025 | Impella |
| Amgen INC. | $864.44 | 2019-2025 | Repatha, Repatha |
| Siemens Medical Solutions USA, INC. | $538.63 | 2022-2024 | Magnetom Sola |
| Edwards Lifesciences Corporation | $514.66 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novartis Pharmaceuticals Corporation | $357.11 | 2019-2025 | |
| Boston Scientific Corporation | $335.37 | 2019-2023 | Watchman Access System |
| Heartflow, INC. | $300.94 | 2022-2023 | Ffrct |
| Janssen Pharmaceuticals, INC | $190.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $179.71 | 2019-2025 | Wainua |
| Actelion Pharmaceuticals US, INC. | $179.60 | 2025 | Uptravi, Opsumit, Opsynvi |
| Novo Nordisk INC | $152.79 | 2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.75 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $150.24 | 2019-2025 | Camzyos, Eliquis |
| Cardiovascular Systems INC. | $144.59 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Dibu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.